Provided by Tiger Fintech (Singapore) Pte. Ltd.

Harrow Health Inc

35.89
-0.2500-0.69%
Post-market: 36.420.5300+1.48%18:33 EDT
Volume:482.02K
Turnover:17.41M
Market Cap:1.32B
PE:-59.12
High:36.93
Open:36.40
Low:35.60
Close:36.14
Loading ...

Harrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars

Reuters
·
17 Jul

Harrow Enters Into Commercialization Agreement With Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

THOMSON REUTERS
·
17 Jul

Harrow Inc - Gains Exclusive U.S. Rights to Ophthalmic Biosimilars

THOMSON REUTERS
·
17 Jul

Harrow Inc - to Assume Commercial Responsibility for Byooviz and Opuviz by 2025

THOMSON REUTERS
·
17 Jul

Harrow Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
11 Jul

Cantor Fitzgerald Initiates Harrow at Overweight With $76 Price Target

MT Newswires Live
·
11 Jul

Lake Street Sticks to Their Buy Rating for Harrow Health (HROW)

TIPRANKS
·
25 Jun

Harrow Inc. Conducted Annual Stockholders Meeting

Reuters
·
20 Jun

Harrow Inc. Appoints Mike Biega as New Vice President of Investor Relations and Communications Amid Leadership Transition

Reuters
·
18 Jun

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

THOMSON REUTERS
·
18 Jun

BTIG Initiates Harrow at Buy With $62 Price Target

MT Newswires Live
·
12 Jun

Opaleye Management Inc. Reports Disposal of Harrow Inc. Common Shares

Reuters
·
12 Jun

Harrow Initiated at Outperform by William Blair

Dow Jones
·
10 Jun

William Blair Initiates Coverage on Harrow With Outperform Rating

MT Newswires Live
·
10 Jun

Harrow Health’s Strategic Expansion and Growth Potential in Branded Pharmaceuticals

TIPRANKS
·
10 Jun

Harrow initiated with an Outperform at William Blair

TIPRANKS
·
10 Jun

Lake Street Remains a Buy on Harrow Health (HROW)

TIPRANKS
·
09 Jun

Harrow acquires commercial rights for Byqlovi 0.05%

TIPRANKS
·
09 Jun

Harrow- Byqlovi Expected to Be Available in Q4 2025

THOMSON REUTERS
·
09 Jun

Harrow Acquires U.S. Commercial Rights to Byqlovi™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% From Formosa Pharmaceuticals

THOMSON REUTERS
·
09 Jun